Annovis Bio Shows Alzheimer’s Reversal in Humans in Phase II Study
"The study involved patients with mild to moderate Alzheimer’s disease. After 25 days, patients showed a 4.4-point improvement in cognition compared to baseline and a 3.3-point improvement compared to placebo, using the 70-point, 11 item Alzheimer’s Disease Assessment Scale (ADAS-11)."